Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840451 | 0.84 | GRM5 (0.48) | GRM5NPC1RAB9APOLBNR2F2 | |
| SCHEMBL3377095 | 0.76 | GRM5 (0.44) | GRM5NPC1RAB9APOLBNR2F2 | |
| SCHEMBL5123963 | 0.75 | GRM5 (0.43) | GRM5PTGESKCNH2MAP3K14 | |
| SCHEMBL5115607 | 0.74 | GRM5 (0.46) | GRM5PTGESKCNH2MAP3K14CYP1A2 | |
| SCHEMBL1899368 | 0.73 | GRM5 (0.49) | GRM5PTGESKCNH2MAP3K14 | |
| SCHEMBL3276812 | 0.73 | GRM5 (0.49) | GRM5PTGESKCNH2MAP3K14 | |
| SCHEMBL5122918 | 0.72 | GRM5 (0.54) | GRM5CYP1A2 | |
| SCHEMBL4046766 | 0.72 | GRM5 (0.41) | GRM5NPC1RAB9APTGESKCNH2 | |
| SCHEMBL1899365 | 0.72 | GRM5 (0.51) | GRM5POLB | |
| SCHEMBL3276329 | 0.72 | GRM5 (0.51) | GRM5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877364-B1 | PHENYLACETYLENE DERIVATIVES HAVING MGLUR5 RECEPTOR AFFINITY | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080188490-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-08-07 | — | — | US | disclosed |
| EP-1877364-A1 | PHENYLACETYLENE DERIVATIVES HAVING MGLUR5 RECEPTOR AFFINITY | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114260-A1 | PHENYLACETYLENE DERIVATIVES HAVING MGLUR5 RECEPTOR AFFINITY | NOVARTIS AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188490-A1 | Acetylene Derivatives | NAT1, CYP1A2, NAT10 | GRM5 3598/4885NPC1 243/4885RAB9A 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.